Fusion already used in industry and medicine
SHINE operates neutron testing services for defense and aerospace components and produces radioisotopes for diagnostic imaging and cancer therapy. Its Ilumira facility produces lutetium-177, used to deliver targeted radiation in cancer treatment.
Capital and isotope supply partnership
NantWorks led the $240 million equity financing. Its founder Patrick Soon-Shiong invested $150 million and joined SHINE’s board. The companies also agreed priority access to SHINE’s Lu-177 supply. The financing advances existing products and the development of used nuclear fuel recycling and commercial fusion energy.